Elevance Health stock gains after 2026 earnings guidance is reaffirmed
Published on 09/10/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock (ISIN US2855211023) jumped sharply on September 10, 2026, with the shares up around 5 percent as investors reacted to management reaffirming full-year 2026 earnings guidance and indicating that third-quarter adjusted earnings are running ahead of the company’s prior outlook.
Guidance reaffirmed and Q3 tracking ahead
According to AnalystLens on September 10, 2026, Elevance Health filed a Form 8-K to reaffirm its full-year 2026 shareholders’ earnings guidance of at least USD 20.10 per diluted share, including roughly USD 6.90 per share of net unfavorable items, and adjusted shareholders’ earnings of at least USD 27.00 per diluted share excluding these items.
As Investing.com reported on September 10, 2026, the company used the Wells Fargo 21st Annual Healthcare Conference to underline that third-quarter 2026 adjusted EPS is currently tracking ahead of the outlook given on the second-quarter earnings call, while maintaining its full-year benefit expense ratio guidance at 90.2 percent plus or minus 50 basis points.
Management also reiterated that operating cash flow for 2026 is expected to be at least USD 6.0 billion and confirmed a 2026 operating margin target of at least 2 percent, alongside a long-term operating margin range of 3 to 5 percent, reinforcing the view that profitability should remain intact even amid elevated medical costs and policy pressures in parts of the business.
Latest reported figures and growth outlook
For context, Elevance’s most recent quarterly results for the second quarter of 2026 showed adjusted EPS of USD 7.45 and revenue of USD 49.83 billion, with the company simultaneously raising its 2026 adjusted EPS guidance to at least USD 27.00 and its 2026 operating cash flow target to at least USD 6.0 billion, according to a summary of the Q2 report cited by MoneyDJ.
The same Q2 2026 snapshot showed the medical benefit expense ratio rising to 89.7 percent and premium revenue around USD 41.3 billion, while total medical membership fell to roughly 44.9 million, with Medicaid membership down about 4 percent year-on-year and Medicare membership down about 11 percent, indicating that the raised guidance is coming despite pressure in key government programs.
At the Wells Fargo conference, management said 2026 is tracking better than expected and projected at least 12 percent adjusted EPS growth in 2027 from the 2026 ending earnings baseline, supported by improved Medicaid margins, continued Medicare Advantage progress and stronger contributions from the Carelon health services segment, according to Investing.com.
Analyst targets and valuation context
Elevance Health continues to attract positive analyst attention. According to MarketBeat on September 10, 2026, TD Cowen recently raised its price objective on Elevance Health shares from USD 400.00 to USD 465.00 with a Buy rating, and the stock carries an average analyst target price of USD 440.90 alongside a consensus rating of Moderate Buy.
Additional data compiled by Quiver Quantitative shows that in the past few months, individual analysts have set targets such as USD 439 by RBC Capital on July 9, 2026, USD 450 by Cantor Fitzgerald on July 7, 2026 and USD 482 by Bernstein on July 2, 2026, with a median target of USD 450, underscoring that the reaffirmed 2026 guidance sits broadly in line with optimistic sell-side expectations.
From a technical perspective, Elevance Health shares have climbed from about USD 275 in early January 2026 to the high USD 300s and low USD 400s, and are trading just above their 50-day moving average with the 200-day moving average around USD 360, as noted by AInvest on September 10, 2026; this implies the stock is up about 35 percent over the recent window yet still roughly 5 percent below its post-Q2 earnings highs.
Risk factors around costs and regulation
Even as the company underscores stronger-than-expected earnings trends, cost and regulatory dynamics remain important risk factors. At the Wells Fargo conference, Elevance management acknowledged that parts of its market continue to face elevated medical costs and policy pressure, including Medicare Advantage and Medicaid, but argued that better rate environments and targeted cost initiatives are supporting margin expectations, according to Investing.com.
The company also reported reaching a final resolution with the Centers for Medicare and Medicaid Services in July 2026 that allows it to continue offering its Medicare Advantage plans without interruption, removing uncertainty around a key growth platform while still leaving execution risk as Elevance works to rebuild membership and manage medical loss ratios in these government programs, as described by Investing.com.
Stock reaction and current price level
Elevance Health’s guidance reaffirmation and conference commentary sparked a notable price reaction. As of the US session on September 10, 2026, one overview of S&P 500 movers listed Elevance Health among the top gainers with the stock around USD 418.26 and up about 5.38 percent on the day on the New York Stock Exchange, while another snapshot showed the shares near USD 412.78 and up about 4.00 percent, illustrating intraday volatility but consistently positive performance.
Elevance Health stock facts
- Company: Elevance Health, Inc.
- ISIN: US2855211023
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 10, 2026): 418.26 USD
- Market capitalization: 99,000,000,000 USD (as of September 10, 2026)
- Sector / Industry: Health Care / Managed Health Care
- Index membership: S&P 500
